electroCore (NASDAQ:ECOR – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare electroCore to related companies based on the strength of its risk, earnings, valuation, profitability, dividends, analyst recommendations and institutional ownership.
Risk & Volatility
electroCore has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, electroCore’s competitors have a beta of 5.41, meaning that their average share price is 441% more volatile than the S&P 500.
Earnings and Valuation
This table compares electroCore and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| electroCore | $37.97 million | -$13.97 million | -3.78 |
| electroCore Competitors | $1.89 billion | $136.85 million | 6.01 |
electroCore’s competitors have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares electroCore and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -33.46% | N/A | -74.21% |
| electroCore Competitors | -300.62% | -179.55% | -22.71% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for electroCore and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| electroCore Competitors | 4309 | 10596 | 18377 | 837 | 2.46 |
electroCore presently has a consensus target price of $18.00, suggesting a potential upside of 242.86%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.20%. Given electroCore’s higher possible upside, analysts plainly believe electroCore is more favorable than its competitors.
Insider and Institutional Ownership
26.7% of electroCore shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 7.8% of electroCore shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
electroCore competitors beat electroCore on 10 of the 13 factors compared.
electroCore Company Profile
electroCore is a medical technology company that develops non-invasive bioelectronic therapies. Its products use non-invasive vagus nerve stimulation (nVNS), which delivers gentle electrical stimulation through the skin to activate the vagus nerve. The company’s gammaCore device is used for the treatment of certain headache conditions, including migraine and cluster headache, subject to its regulatory clearances and indications. electroCore also offers Truvaga, a consumer wellness product that uses non-invasive vagus nerve stimulation.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
